<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495272</url>
  </required_header>
  <id_info>
    <org_study_id>Kanuni-Bagcilar</org_study_id>
    <nct_id>NCT02495272</nct_id>
  </id_info>
  <brief_title>Postpartum Uterotonic Administration</brief_title>
  <official_title>The Effect of the Timing of Uterotonic Administration in the Third Stage of Labour on Postpartum Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bagcilar Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kanuni Sultan Suleyman Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bagcilar Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are planning to determine the effect of the timing of oxytocin
      administration on the amount of blood loss, necessity for additional medical or surgical
      interventions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are studying the effects of the timing of intramuscular oxytocin
      administration in the third stage of labour. The investigators are measuring the postpartum
      blood loss: quantitatively in the postpartum 1st hour and indirectly by the decrease in the
      hemoglobin-haematocrit levels in the postpartum 24th hour. The investigators are monitoring
      the length of the third stage of labour, and the need for extra uterotonics and/or surgical
      interventions.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postpartum blood loss</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 24 hour</time_frame>
    <description>Quantitative collection of blood loss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postpartum blood loss &gt;500cc</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 24 hour</time_frame>
    <description>Number of participants whose blood loss is higher than 500cc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for additional uterotonics</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 24 hour</time_frame>
    <description>Additional uterotonics (Oxytocin 10IU; Cytotec tb Rectal and/or vaginal) were administered if postpartum blood loss &gt;500ml OR uterine atony was observed OR sudden excessive hemorrhage was encountered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum transfusion</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 24 hour.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manual removal of the placenta.</measure>
    <time_frame>At first hour after delivery of the fetus</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the third stage of labour.</measure>
    <time_frame>Participants will be followed for the duration of labor unit stay, an expected average of one hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop in the hemoglobin and hematocrit levels</measure>
    <time_frame>At the 24th hour,postpartum</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Postpartum Bleeding</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxytocin 10IU im was administered after placental delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin 10IU im was administered after the anterior shoulder could be seen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Oxytocin 10IU Administered intramuscularly.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Study Group</arm_group_label>
    <other_name>PostuitrinFort Amp I.E.Ulagay</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cephalic presentation

          -  Singleton pregnancy

          -  Gestational age &gt;35 weeks,

          -  In active labour.

          -  Expected fetal birth weight 2500-4500 grams.

        Exclusion Criteria:

          -  Acute Fetal Distress

          -  Conversion to abdominal delivery

          -  Persistent high blood pressure (&gt;140/90mmHg)

          -  Placenta Previa

          -  Ablatio placenta

          -  Previous C-Section

          -  Uterine scar

          -  Postpartum hemorrhage in previous pregnancies.

          -  Hydramnios

          -  Maternal infection

          -  Forceps/Vacuum Assisted deliveries

          -  Abnormal placentation ( Placenta accreta, increta or percreta)

          -  Coagulation Defects

          -  Hemoglobin &lt; 8g/dl
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Burak Ozkose, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kanuni Sultan Suleyman Teaching and Research Hospital, Istanbul</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dogukan Yildirim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kanuni Sultan Suleyman Teaching and Research Hospital, Istanbul</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eser S Ozyurek, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Bagcilar Training and Research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Batuhan Ustun, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kanuni Sultan Suleyman Teaching and Research Hospital, Istanbul</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dogukan Yildirim, MD</last_name>
    <phone>+905063284383</phone>
    <email>dogukanyildirim@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eser S Ozyurek, MD</last_name>
    <phone>+905309322345</phone>
    <email>eozyurek@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kanuni Sultan Suleyman Teaching and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dogukan Y覺ld覺r覺m, MD</last_name>
      <phone>+905063284383</phone>
      <email>dogukanyildirim@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Oguz Orhan E, Dilbaz B, Aksakal SE, Alt覺nbas S, Erkaya S. Prospective randomized trial of oxytocin administration for active management of the third stage of labor. Int J Gynaecol Obstet. 2014 Nov;127(2):175-9. doi: 10.1016/j.ijgo.2014.05.022. Epub 2014 Jul 17.</citation>
    <PMID>25108586</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2015</study_first_submitted>
  <study_first_submitted_qc>July 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2015</study_first_posted>
  <last_update_submitted>July 8, 2015</last_update_submitted>
  <last_update_submitted_qc>July 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bagcilar Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Eser Sefik Ozyurek</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Postpartum hemorrhage</keyword>
  <keyword>Third stage of labour</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Uterotonics</keyword>
  <keyword>Active management of third stage of labour</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

